PBLS Parabilis Medicines, Inc.
Executive Summary
Parabilis Medicines, a clinical-stage biopharmaceutical company developing Helicon therapeutics for undruggable targets, filed Amendment No. 3 to its S-1 registration statement, setting an IPO price range of $17.00-$19.00 per share for 33,333,334 shares. Concurrently, Regeneron will invest $75.0 million in a private placement at 90% of the IPO price, complementing a $50.0 million upfront from a May 2026 collaboration. Proceeds will fund clinical development of lead candidate zolucatetide in desmoid tumors and other indications, advance preclinical pipeline, and support general operations, extending cash runway into H2 2029.
Key Financial Metrics
Actionable Insight
Monitor the IPO pricing and first-day trading for demand signals. The Regeneron collaboration and private placement provide strong validation and a capital cushion, but the stock will be volatile as a pre-revenue biotech. Key catalysts to watch: initiation of the Phase 3 desmoid tumor trial (H1 2027) and data readouts from ongoing Phase 1/2 studies in FAP, HCC, and other indications.
Key Facts
- IPO price range set at $17.00-$19.00 per share for 33,333,334 shares.
- Regeneron to purchase $75.0 million of common stock in a concurrent private placement at 90% of the IPO price.
- Regeneron also provided a $50.0 million upfront payment under a May 2026 License and Collaboration Agreement.
- Estimated net IPO proceeds of ~$553.1 million (or ~$636.8 million with overallotment), plus $75.0 million from the private placement.
- Pro forma as adjusted cash and cash equivalents of ~$957.1 million, funding operations into H2 2029.
- Lead candidate zolucatetide showed 74% objective response rate in desmoid tumors with 100% disease control rate in evaluable patients.
- Fast Track and Orphan Drug Designations granted for zolucatetide in desmoid tumors.
- Net losses of $145.9 million (FY2025) and $45.3 million (Q1 2026), with accumulated deficit of $586.8 million as of March 31, 2026.
Financial Impact
IPO expected to raise ~$553.1M net ($636.8M with overallotment) plus $75M from Regeneron private placement, extending cash runway into H2 2029.
Risk Factors
- Clinical-stage company with no approved products or revenue; high development risk.
- Dependence on success of zolucatetide; Phase 3 trial may fail or be delayed.
- Novel Helicon modality unproven at scale; regulatory and manufacturing risks.
- Substantial ongoing losses and need for future capital beyond IPO proceeds.
- Competition from existing therapies (e.g., GSI for desmoid tumors) and other drug developers.
- Dilution to existing shareholders from IPO and future equity raises.
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-262880 |
| Document: ck0001657677-exfiling_fees.htm | 0001193125-26-262880 |
| Document: ck0001657677-ex5_1.htm | 0001193125-26-262880 |
| Document: ck0001657677-ex23_1.htm | 0001193125-26-262880 |
| Document: 0001193125-26-262880-index-headers.html | 0001193125-26-262880 |
| Document: 0001193125-26-262880-index.html | 0001193125-26-262880 |
| Document: 0001193125-26-262880.txt | 0001193125-26-262880 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $30.30 awaiting T+20 | awaiting T+20 | — | $27.26 (−10.03%) |
|
Jun 10, 2026
4d ago
|
424B4
| $32.16 awaiting T+20 | awaiting T+20 | — | $27.26 (−15.24%) |
|
Jun 10, 2026
5d ago
|
EFFECT
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
Press Release
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access